MYCN and neoplasm: MYCN downregulation precedes RA-induced differentiation121 and its genetic silencing via siRNA or inhibition with the BET inhibitor JQ1 resulted in neuronal differentiation in vitro and reduced tumor burden in vivo.122,123 The newer IBET-762 and OTX-015 BET inhibitors were tested in clinical trials for the treatment of hematopoietic and solid tumors.